No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment leads to higher loss of fewer than 15 letters visual acuity at 1 year compared with control (high certainty).
1 finding from 1 review
Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration
1 finding from 1 review
Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vision‐related quality of life · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in gain of 15 or more letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Visual acuity · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
2 findings from 1 review
Adherence · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Ocular alignment (different measures and time points reported in the included studies) Assessed at different time points (17 weeks, 24 months, or cessation of treatment) and by the proportions of participants who developed strabismus, showed chang... · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Stereo acuity (different measures and time points reported in the included studies) Assessed at different time points (17 weeks, 6 months, 2 years, or at cessation of treatment) and using different measures (TNO stereo test, Titmus fly test, Rando... · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Quality of life (different measures and time points reported in the included studies) Assessed at different time points (17 weeks or 6 months) by patient preference or the Amblyopia Treatment Index questionnaire. · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Adverse events (reported occurrence of: mild reduction in the visual acuity of the sound eye not requiring treatment; light sensitivity; skin, lid, or conjunctival irritation) Assessed at different time points (17 weeks or 2 years). · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Medical adverse events up to 2 months after surgery · people with age‐related cataract
Routine preoperative medical testing showed no clear difference in medical adverse events up to 2 months after surgery compared with selective or no testing (high certainty).
1 finding from 1 review
Adverse events (ocular problems) · people with age‐related cataract
Routine preoperative medical testing showed no clear difference in ocular adverse events up to 2 months after surgery compared with selective or no testing (moderate certainty).
1 finding from 1 review
Cost for preoperative testing prior to surgery · people with age‐related cataract
1 finding from 1 review